甲状旁腺素对人甲状腺髓样癌细胞增殖和凋亡的影响(3)
 |
| 第1页 |
参见附件。
[11] Li Z， Sturm S， Svejda B， et al.Anticancer activity of novel extracts from Cautleya gracilis (Smith) Dandy：apoptosis inhuman medullary thyroid carcinoma cells[J].Anticancer Res，2008，28(5A)：2705-2713.
[12] Robinson BG，Paz-Ares L，Krebs A，et al.Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer[J].Clin Endocrinol Metab，2010，95(6)：2664-2671.
[13] Kurzrock R，Sherman SI，Ball DW，et al.Activity of XL184 (Cabozantinib)， an oral tyrosine kinase inhibitor，in patients with medullary thyroid cancer[J].Clin Oncol，2011，29(19)：2660-2666.
[14] Sherman SI.Targeted therapy of thyroid cancer[J].Biochem Pharmacol，2010，80(5)：592-601.
[15] Baldini E，Arlot-Bonnemains Y，Sorrenti S，et al.Aurora kinases are expressed in medullary thyroid carcinoma(MTC)and their inhibitionsuppresses in vitro growth and tumorigenicity of the MTC derived cell line TT[J].BMC Cancer，2011，11(2)：411.
[16] Chung YJ，Lee JI，Chong S，et al.Anti-proliferative effect and action mechanism of dexamethasone in human medullary thyroid cancer cell line[J].Endocr Res，2011，36(4)：149-157.
[17] Molè D，Gentilin E，Gagliano T，et al.Protein kinase C：a putative new target for the control of human medullary thyroidcarcinoma cell proliferation in vitro[J].Endocrinology，2012，153(8)：2088-2098.
(收稿日期：2013-12-14)
您现在查看是摘要介绍页，详见PDF附件。